SS18L2 and lung cancer: A subset of the 11 gene signature has recently been reported in the context of lung cancer, either as an oncogenic driver (e.g. CD79B [32]) or a prognostic marker (e.g. TRAF3IP3, SKAP2, and SS18L2) [33–35].